• Publications
  • Influence
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment
JNJ‐56914845 (GSK2336805) is a hepatitis C virus nonstructural protein 5A inhibitor under development for the treatment of chronic hepatitis C (CHC) infection. This open‐label, parallel‐group, 2‐partExpand
  • 2
GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects
GSK2878175 is a potent, pan‐genotypic, non‐nucleoside, nonstructural protein 5B palm polymerase inhibitor being developed for the treatment of chronic hepatitis C (CHC). A first‐in‐human, randomized,Expand
  • 4
Impact and Etiology of Periungual Toe Infections in Neutropenic Patients
MethodsA chart review of the patients who had positive cultures of the nail for fungal infection from 1985 to June 2011 was conducted at Moffitt Cancer Center. ResultsTwenty-six patients with nailExpand
  • 1